BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15906167)

  • 1. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen.
    Weitschies W; Bernsdorf A; Giessmann T; Zschiesche M; Modess C; Hartmann V; Mrazek C; Wegner D; Nagel S; Siegmund W
    Pharm Res; 2005 May; 22(5):728-35. PubMed ID: 15906167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans.
    Gramatté T; Oertel R; Terhaag B; Kirch W
    Clin Pharmacol Ther; 1996 May; 59(5):541-9. PubMed ID: 8646825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
    Westphal K; Weinbrenner A; Giessmann T; Stuhr M; Franke G; Zschiesche M; Oertel R; Terhaag B; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2000 Jul; 68(1):6-12. PubMed ID: 10945310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein and surfactants: effect on intestinal talinolol absorption.
    Bogman K; Zysset Y; Degen L; Hopfgartner G; Gutmann H; Alsenz J; Drewe J
    Clin Pharmacol Ther; 2005 Jan; 77(1):24-32. PubMed ID: 15637528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.
    Schwarz UI; Gramatté T; Krappweis J; Oertel R; Kirch W
    Int J Clin Pharmacol Ther; 2000 Apr; 38(4):161-7. PubMed ID: 10783825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.
    Schwarz UI; Gramatté T; Krappweis J; Berndt A; Oertel R; von Richter O; Kirch W
    Clin Pharmacol Ther; 1999 Mar; 65(3):283-90. PubMed ID: 10096260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
    Han Y; Guo D; Chen Y; Tan ZR; Zhou HH
    Xenobiotica; 2009 Sep; 39(9):694-9. PubMed ID: 19555315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol.
    Spahn-Langguth H; Langguth P
    Eur J Pharm Sci; 2001 Feb; 12(4):361-7. PubMed ID: 11231102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers.
    Yan M; Fang PF; Li HD; Xu P; Liu YP; Wang F; Cai HL; Tan QY
    Eur J Clin Pharmacol; 2013 Mar; 69(3):515-21. PubMed ID: 22983284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.
    Tubic M; Wagner D; Spahn-Langguth H; Weiler C; Wanitschke R; Böcher WO; Langguth P
    Eur J Pharm Sci; 2006 Nov; 29(3-4):231-9. PubMed ID: 16713700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.
    Wetterich U; Spahn-Langguth H; Mutschler E; Terhaag B; Rösch W; Langguth P
    Pharm Res; 1996 Apr; 13(4):514-22. PubMed ID: 8710739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets.
    Siegmund W; Ludwig K; Engel G; Zschiesche M; Franke G; Hoffmann A; Terhaag B; Weitschies W
    J Pharm Sci; 2003 Mar; 92(3):604-10. PubMed ID: 12587122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers.
    Juan H; Terhaag B; Cong Z; Bi-Kui Z; Rong-Hua Z; Feng W; Fen-Li S; Juan S; Jing T; Wen-Xing P
    Eur J Clin Pharmacol; 2007 Jul; 63(7):663-8. PubMed ID: 17468862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man.
    Trausch B; Oertel R; Richter K; Gramatté T
    Biopharm Drug Dispos; 1995 Jul; 16(5):403-14. PubMed ID: 8527689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
    Schwarz UI; Hanso H; Oertel R; Miehlke S; Kuhlisch E; Glaeser H; Hitzl M; Dresser GK; Kim RB; Kirch W
    Clin Pharmacol Ther; 2007 May; 81(5):669-78. PubMed ID: 17392718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers.
    Krueger M; Achenbach H; Terhaag B; Haase H; Richter K; Oertel R; Preiss R
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):61-6. PubMed ID: 11270803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.
    Bernsdorf A; Giessmann T; Modess C; Wegner D; Igelbrink S; Hecker U; Haenisch S; Cascorbi I; Terhaag B; Siegmund W
    Br J Clin Pharmacol; 2006 Apr; 61(4):440-50. PubMed ID: 16542205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance.
    Okyar A; Dressler C; Hanafy A; Baktir G; Lemmer B; Spahn-Langguth H
    Chronobiol Int; 2012 May; 29(4):443-53. PubMed ID: 22489638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of food intake on the delivery of fluorescein as a model drug in colon delivery capsule after oral administration to beagle dogs.
    Matsuda K; Takaya T; Shimoji F; Muraoka M; Yoshikawa Y; Takada K
    J Drug Target; 1996; 4(2):59-67. PubMed ID: 8894965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
    Westphal K; Weinbrenner A; Zschiesche M; Franke G; Knoke M; Oertel R; Fritz P; von Richter O; Warzok R; Hachenberg T; Kauffmann HM; Schrenk D; Terhaag B; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2000 Oct; 68(4):345-55. PubMed ID: 11061574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.